Nevertheless, our study revealed that for tumors with low levels of CD8+ TILs or PD-L1+ tumor cells at screening, no differences in ORR or PFS were observed between the two treatment arms, indicating no added benefit of using BEMPEG + NIVO combination therapy over NIVO monotherapy in this subgroup. The gene discussed is CD8A; the disease is neoplasm.